179 related articles for article (PubMed ID: 38318175)
21. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
22. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
23. SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth.
Su S; Chen J; Jiang Y; Wang Y; Vital T; Zhang J; Laggner C; Nguyen KT; Zhu Z; Prevatte AW; Barker NK; Herring LE; Davis IJ; Liu P
Adv Sci (Weinh); 2021 Jul; 8(14):e2004846. PubMed ID: 34060252
[TBL] [Abstract][Full Text] [Related]
24. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
[TBL] [Abstract][Full Text] [Related]
25. The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer.
Lichtenegger E; Koll F; Haas H; Mantwill K; Janssen KP; Laschinger M; Gschwend J; Steiger K; Black PC; Moskalev I; Nawroth R; Holm PS
Hum Gene Ther; 2019 Jan; 30(1):44-56. PubMed ID: 29916265
[TBL] [Abstract][Full Text] [Related]
26. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
27. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors.
Lun X; Ruan Y; Jayanthan A; Liu DJ; Singh A; Trippett T; Bell J; Forsyth P; Johnston RN; Narendran A
Mol Oncol; 2013 Oct; 7(5):944-54. PubMed ID: 23816608
[TBL] [Abstract][Full Text] [Related]
28. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
Pedersen EA; Menon R; Bailey KM; Thomas DG; Van Noord RA; Tran J; Wang H; Qu PP; Hoering A; Fearon ER; Chugh R; Lawlor ER
Cancer Res; 2016 Sep; 76(17):5040-53. PubMed ID: 27364557
[TBL] [Abstract][Full Text] [Related]
29. Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.
Altvater B; Kailayangiri S; Theimann N; Ahlmann M; Farwick N; Chen C; Pscherer S; Neumann I; Mrachatz G; Hansmeier A; Hardes J; Gosheger G; Juergens H; Rossig C
Cancer Immunol Immunother; 2014 Oct; 63(10):1047-60. PubMed ID: 24973179
[TBL] [Abstract][Full Text] [Related]
30. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
31. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
32. Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy.
Deng X; Shen Y; Yi M; Zhang C; Zhao B; Zhong G; WeiyangLou ; Xue D; Leng Q; Ding J; Zhao R; Jia W; Dong C; Dai Z
J Med Virol; 2023 May; 95(5):e28768. PubMed ID: 37212336
[TBL] [Abstract][Full Text] [Related]
33. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
34. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
35. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
[TBL] [Abstract][Full Text] [Related]
36. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
[TBL] [Abstract][Full Text] [Related]
37. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
38. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma.
Luo W; Hoang H; Liao Y; Pan J; Ayello J; Cairo MS
Front Immunol; 2023; 14():1277987. PubMed ID: 37868989
[TBL] [Abstract][Full Text] [Related]
39. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.
Nishio N; Diaconu I; Liu H; Cerullo V; Caruana I; Hoyos V; Bouchier-Hayes L; Savoldo B; Dotti G
Cancer Res; 2014 Sep; 74(18):5195-205. PubMed ID: 25060519
[TBL] [Abstract][Full Text] [Related]
40. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
